|Pts (%)||3-yr DSS (%)||5-yr DSS (%)|
|sFLC ratio <median and ISS I or II||61 (29)||95||90|
|Either sFLC ratio >median or ISS III||96 (46)||82||56|
|sFLC ratio >median and ISS III||50 (24)||37||24|
Table 20.2. Disease specific survival (DSS) in 207 newly diagnosed patients with MM according to the combined sFLC κ/λ ratios and the ISS comprising serum albumin and β2-microglobulin . (Courtesy of M.C. Kyrtsonis). used extreme κ/λ sFLC ratios (<0.03 or >32) as an additional risk factor to those of the ISS (serum β2M >3.5 g/L, serum albumin <35 g/L) to separate patients (n=790) into four groups with 0, 1, 2, or 3 risk factors. These groups had median overall survival of 51, 39, 30 and 22 months, respectively (p<0.001). Because these data provided additional outcome information, it was suggested that sFLC ratios should be incorporated into the ISS to provide a new risk stratification model. In a study including 122 Chinese MM patients, Xu et al.  used similar κ/λ sFLC ratio boundaries (<0.04 or >25) to add a third risk factor to the ISS. This produced four patient groups with clearly separate survival curves (Figure 20.4) and the authors again concluded that the prognostic potential of the ISS could be improved by incorporating sFLC ratios.
Further evidence of the independence of sFLC ratios as a risk factor was provided by Esteves and colleagues , who used abnormal κ/λ ratios (<0.03 or >32) to separate patients within the ISS stage II into groups with different overall survival. In this study, however, the ratio did not provide further discrimination for patients in ISS stages I or III.